|
Hong Kong Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Hong Kong Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Hong Kong.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Hong Kong pharmaceutical and healthcare industry.
Competitive intelligence, Hong Kong pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Hong Kong market.
The Hong Kong Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Hong Kong Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Hong Kong pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Hong Kong to test other views – a key input for successful budgeting and strategic business planning in the Hong Kong pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Hong Kong Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Hong Kong.
- Exploit The Latest Competitive Hong Kong Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Hong Kong.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Hong Kong Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| Hong Kong Pharmaceuticals And Healthcare Industry SWOT |
| Hong Kong Political SWOT |
| Hong Kong Economic SWOT |
| Hong Kong Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q209 |
| Limits of Potential Returns |
| Risks to Realisation of Returns |
Chapter - Hong Kong – Market Summary |
| Regulatory Regime |
| Intellectual Property Issues |
| Counterfeit Drugs |
| Pricing and Reimbursement Developments |
| Public Procurement of Medicines |
Chapter - Industry Trends and Developments |
| Epidemiology |
| Communicable Diseases |
| Healthcare Sector |
| Table: Secondary/Tertiary Public Sector Health Services In Hong Kong |
| Healthcare Sector Reforms |
| Healthcare Financing |
| Recent Developments in Healthcare Financing |
| Pharmaceutical Industry |
| Traditional Chinese Medicines |
| Foreign Industry Developments |
| Supply Chain |
| Hospital Pharmacy Sector |
| Research And Development |
| Medical Devices |
| Table: Examples Of Medical Devices |
| Overall Market Forecast |
| Table: Hong Kong – Drug Expenditure Indicators, Historical Data And Forecasts |
| Key Growth Factors – Industry |
| Table: Hong Kong – Health Expenditure Indicators, Historical Data And Forecasts |
| Key Growth Factors – Macroeconomic |
| Table: Hong Kong - Economic Activity |
| Prescription Market Forecast |
| Table: Hong Kong – Prescription Market Indicators, Historical Data And Forecasts (HKDmn unless otherwise stated) |
| Patented Drug Market Forecast |
| Table: Hong Kong – Patented Market Indicators, Historical Data And Forecasts |
| Generic Drug Market Forecasts |
| Table: Hong Kong – Generic Market Indicators, Historical Data And Forecasts |
| OTC Market Forecast |
| Table: Hong Kong – OTC Market Indicators, Historical Data And Forecasts (HKDmn unless otherwise stated) |
| Pharmaceutical Trade Forecasts |
| Table: Hong Kong – Pharmaceuticals Export/Import Indicators, Historical Data And Forecasts (US$mn) |
| Other Healthcare Indicators |
| Table: Hong Kong – Other Healthcare Indicators, Historical Data and Forecasts |
| Key Risks to BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Table: Hong Kong's Leading Drugmakers And Products, Q406 |
Chapter - Company Profiles |
| Leading Multinational Companies |
| GlaxoSmithKline |
| Pfizer |
| Sanofi-Aventis |
| Merck & Co |
| Novartis |
| Local Pharmaceutical Companies |
| Wuyi International Pharmaceutical |
| CK Life Sciences |
| South Asia Pharmamedic Ltd |
| C&Y Pharmaceutical Investment Holding |
| Vida Laboratories |
Chapter - Country Snapshot: Hong Kong Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown |
| Section 2: Education And Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Employment Indicators, 2001-2006 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Table: Average Annual Wages, 2005-2012 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Hong Kong Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
In BMI’s Asia Pacific Pharmaceuticals & Healthcare Business Environment Ranking table for Q209, Hong Kong’s pharmaceutical market is found in an improved fifth place, out of the 15 key markets in the Asia Pacific region. The country’s main disadvantages include its small population and a relative maturity of its pharmaceutical market, although the latter will likely result in Hong Kong being overtaken in the course of the next five years by larger, emerging regional markets, such as India. Nevertheless, through to 2013, the pharmaceutical market of Hong Kong is expected to grow at a steady compound annual growth rate (CAGR) of 4.77% in local currency terms. This growth rate will put the 2013 value of the market at HKD9.24bn (US$1.185bn) at consumer prices, up from HKD7.32bn (US$0.939bn) in 2008.
Key drivers of pharmaceutical growth will remain the preference for branded drugs, a strong healthcare system, comprising both public and private provision, and a highly urbanised and ageing population, increasingly suffering from chronic and long-term diseases. In fact, by 2031, the portion of people older than 65 is expected to top 24% of the total population, up from around 12% at present. On the negative side, the pricing and reimbursement environment can be slightly erratic, although Hong Kong’s political situation and its relationship with mainland China will continue to pose relatively few problems to investment.
In the meantime, Hong Kong's economy looks set to be impacted by global financial crisis more violently than initially anticipated. In particular, the services sector, which had held up relatively well in Q308, is expected to show sharp declines in the coming quarters as demand for trade and finance-related services falter. We have further lowered our forecast for GDP growth in 2009 to -3.6%, following a 2.5% contraction in 2008, and anticipate a mild recovery in 2010. Moreover, the recently unveiled budget, which envisages higher funding for medical services over the next three years, may be not be aggressive enough in the current economic downturn. Despite an increase in funding, healthcare services may find themselves stretched by the influx of new users of public hospitals, who can no longer afford private insurance.
A second phase of public consultation on the matter of healthcare reform took place in February 2009, with the public generally supportive of the proposals that include the development of primary care, and the encouragement of the public-private partnerships under the 'money follows patient' concept. However, no consensus was achieved on the preferable option to finance the changes, with speculations rife that a combination of social and mandatory health insurance and out-of-pocket payments will be adopted. In fact, according to the Food and Health Bureau, private sector's contribution to spending will drop from 44.3% in 2004 to 40.8% in 2033, although as the Hospital Authority (HA) is already running a high deficit, questions can be raised over its longer-term viability if its operating premises remain unchanged.
|
Hong Kong Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |